title: Testosterone Therapy Can Interact With Thrombophilia, Leading to Osteonecrosis.
abstract: Although this effect is not widely recognized, testosterone therapy can interact with thrombophilia, causing osteonecrosis. In 12 men and 4 women who had idiopathic osteonecrosis a median of 6 months after the onset of testosterone therapy, the authors examined the interaction between testosterone therapy and previously undiagnosed thrombophilia. The authors hypothesized that patients who had osteonecrosis after starting testosterone therapy were more likely than 110 normal control subjects or 48 patients who had osteonecrosis and were not receiving testosterone therapy to have thrombophilia. Measures of thrombophilia included Factor V Leiden, prothrombin, PAI-1 gene mutations, Factor VIII, Factor XI, anticardiolipin antibody immunoglobulin G or immunoglobulin M, and homocysteine values. In 10 cases, osteonecrosis occurred 6 months or less after the onset of testosterone therapy, and in all 16 cases, it occurred after a median of 6 months of testosterone therapy. Of the 16 cases, 5 (31%) were Factor V Leiden heterozygotes vs 2 of 109 (2%) healthy control subjects (P=.0003) and 4 of 48 patients who had osteonecrosis and were not receiving testosterone therapy (P=.04). Of the 16 cases, 4 (25%) had high (>150%) Factor VIII levels vs 7 of 103 (7%) healthy control subjects (P=.04), and 3 (19%) had high (>150%) Factor XI levels vs 3 of 101 (3%) healthy control subjects (P=.03). Of the 16 patients with osteonecrosis, 14 (88%) had at least 1 abnormal procoagulant value (of the 8 measured) vs 47 of 110 (43%) healthy control subjects (P=.0009). Of the 5 men whose serum estradiol level was measured while they were receiving testosterone therapy, this level was high (≥42.6 pg/mL) in 4. When testosterone therapy is given to patients with thrombophilia, they are at increased risk for osteonecrosis.
authors.forename: Charles J
authors.initials: CJ
authors.lastname: Glueck
authors.forename: Rashid
authors.initials: R
authors.lastname: Riaz
authors.forename: Marloe
authors.initials: M
authors.lastname: Prince
authors.forename: Richard A
authors.initials: RA
authors.lastname: Freiberg
authors.forename: Ping
authors.initials: P
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D000728:Androgens / Q000009:adverse effects*; D016022:Case-Control Studies; D005165:Factor V; D005169:Factor VIII / Q000235:genetics; D005260:Female; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy; D007989:Libido / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics; D010020:Osteonecrosis / Q000139:chemically induced*; D017395:Plasminogen Activator Inhibitor 1 / Q000235:genetics; D011516:Prothrombin / Q000235:genetics; D013739:Testosterone / Q000009:adverse effects*; D019851:Thrombophilia / Q000150:complications* / Q000235:genetics
chemical_list: D000728:Androgens; D017395:Plasminogen Activator Inhibitor 1; C051321:SERPINE1 protein, human; C095381:factor V Leiden; C427184:recombinant factor VIII SQ; D013739:Testosterone; D005165:Factor V; D011516:Prothrombin; D005169:Factor VIII